3billion to Present on Rare Disease Genomic Diagnostics and Reanalysis at Two European Conferences in June 2026
核心洞察
3billion (搜索) will deliver two presentations at the Genomic and Genetic Technologies in Clinical Practice conference in Almaty, Kazakhstan, on June 3–4, 2026, focusing on expanding rare disease (搜索) diagnosis and the clinical impact of genetic data reanalysis.
The company will also exhibit at the ESHG Conference 2026 in Gothenburg, Sweden, from June 13–16, showcasing comprehensive genetic testing services, a newborn screening test (3B-NEO), and the Family Insight Test.
The Almaty presentations will address how evolving genomic technologies improve diagnostic access and how reanalysis of previously inconclusive genetic data can yield new answers for patients.
3billion (搜索), a genetic testing company focused on rare disease (搜索) diagnostics, is set to make a significant presence at two major European conferences in June 2026, highlighting its evolving genomic solutions and the growing clinical utility of genetic data reanalysis.
The company will first participate in the Genomic and Genetic Technologies in Clinical Practice conference, taking place June 3–4, 2026, at Narxoz Business School in Almaty, Kazakhstan. The event convenes clinical geneticists and genomic specialists to explore the expanding role of genetic technologies in routine clinical care.
Two presentations from 3billion (搜索) are scheduled. Minsoo Kim will present "Expanding Rare Disease (搜索) Diagnosis: 3billion's Evolving Genetic Solutions" from 12:30 to 13:00, detailing how genomic technologies are improving access to rare disease diagnosis. Later, Yoo Hyun Kim will deliver "The Clinical Impact of Reanalysis in Rare Diseases" from 13:50 to 14:10, focusing on how reanalysis of existing genetic data can surface new answers for patients who previously received inconclusive results.
"Together, they reflect 3billion (搜索)'s focus on moving the diagnostic process forward—both for clinicians navigating complex cases and for patients still waiting for answers," the company stated in its announcement.
Later in June, 3billion (搜索) will exhibit at the European Society of Human Genetics (ESHG) Conference 2026 in Gothenburg, Sweden, from June 13–16 at Booth #620. The company plans to showcase three key solutions: comprehensive genetic testing services built to support rare disease (搜索) diagnosis; 3B-NEO, a genetic screening test for newborns; and the Family Insight Test, which adds carriership findings so families gain genetic insight that reaches beyond a single diagnosis.
At ESHG, 3billion (搜索) aims to engage with clinicians and researchers seeking to improve diagnostic yield, widen testing offerings, and explore the future direction of genomic healthcare. "We'd welcome the chance to talk through the diagnostic challenges you're working on," the company noted, inviting attendees to discuss how its solutions can integrate into clinical practice and research workflows.